BioMarin Announces Second Quarter 2018 Results

Published: Aug 02, 2018

 

- Total Revenues of $372.8 million in the Quarter
- Received Approval of its Seventh Commercial Product, Palynziq™ Injection for Treatment of Adults with Phenylketonuria
- Provided Two Years of Clinical Data from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia; Amended Phase 3 Protocol to Evaluate Superiority to the Current Standard of Care

SAN RAFAEL, Calif., Aug. 2, 2018 /PRNewswire/ -- BioMarin Second Quarter 2018 Results

    Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)



                                                                          Three Months Ended June 30,                              Six Months Ended June 30,
                                                                          ---------------------------                              -------------------------

                                                                2018                                           2017              %                              2018  2017                 %
                                                                                                                             Change                                                  Change
                                                                                                                             ------                                                  ------


    Total Revenues                                                                      $372.8                        $317.4                                     17%          $746.3                 $621.2        20%

    Vimizim Net Product
     Revenues                                                                            127.6                         103.2                                     24%           244.7                  209.0        17%

    Kuvan Net Product
     Revenues                                                                            109.0                         102.0                                      7%           208.1                  194.3         7%

    Naglazyme Net Product
     Revenues                                                                             91.1                          85.7                                      6%           166.1                  166.3     -

    Aldurazyme Net Product
     Revenues                                                                             24.0                          19.9                                     21%            90.1                   39.3       129%

    Brineura Net Product
     Revenues                                                                             10.9                           0.3                                n/a      17.8                    0.3            n/a


    GAAP Net Loss                                                                      $(16.8)                      $(36.8)                                                $(60.9)               $(53.1)

    GAAP Net Loss per Share
     -Basic and Diluted                                                                $(0.09)                      $(0.21)                                                $(0.35)               $(0.31)


    Non-GAAP Income (1)                                                                  $19.9                         $26.6                                                   $41.2                  $61.0


                                                           June 30,                                   December 31,

                                                                2018                                           2017
                                                                ----                                           ----

    Cash, cash equivalents
     and investments                                                                  $1,643.1                      $1,781.7

    (1)              Non-GAAP Income is defined by the
                     Company as reported GAAP Net
                     Income (Loss), excluding net
                     interest expense, provision for
                     (benefit from) income taxes,
                     depreciation expense, amortization
                     expense, stock-based compensation
                     expense, contingent consideration
                     expense and, in certain periods,
                     certain other specified items.
                     Refer to Non-GAAP Information
                     beginning on page 9 of this press
                     release for a complete discussion
                     of the Company's Non-GAAP
                     financial information and
                     reconciliations to the comparable
                     information reported under
                     Generally Accepted Accounting
                     Principles in the United States
                     (US GAAP).

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2018. The financial results that follow represent a comparison of the second quarter of 2018 to the second quarter of 2017. Total revenues were $372.8 million for the quarter ended June 30, 2018 compared to $317.4 million for the quarter ended June 30, 2017, an increase of 17%. GAAP Net Loss for the quarter ended June 30, 2018 was $16.8 million, or $0.09 loss per basic and diluted share compared to GAAP Net Loss of $36.8 million, or $0.21 loss per basic and diluted share for the quarter ended June 30, 2017.

Net product sales for the second quarter of 2018 were $367.8 million, compared to $315.9 million in the second quarter of 2017. The increase in net product sales was attributed to the following:

  • Vimizim: increased by $24.4 million, or 24%, due primarily to an increase in the number of commercial patients;
  • Brineura: launched in the second quarter of 2017, and contributed $10.6 million to increased net product revenues;
  • Kuvan: increased $7.0 million, or 7%, driven by an increase in the number of commercial patients;
  • Naglazyme: increased $5.4 million, or 6%, primarily due to government ordering patterns in certain countries and an increase in the number of commercial patients; and
  • Aldurazyme: increased $4.1 million, or 21%, primarily as a result of increased volume.

The decrease in GAAP Net Loss was primarily due to the following:

  • Increased gross profit primarily driven by increased Vimizim, Brineura and Kuvan net product revenues; and
  • A gain on the sale of intangible assets totaling $20.0 million received from Pfizer Inc. (Pfizer) associated with the achievement of two regulatory milestones, triggered by the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application submission for talazoparib (which BioMarin sold to Medivation Inc. prior to Pfizer's acquisition of Medivation Inc.) and the European Medicines Agency acceptance of Pfizer's submission of a Marketing Authorization Application for talazoparib; partially offset by
  • Higher research and development (R&D) expense for the expansion of our clinical programs related to tralesinidase alfa (formally referred to as BMN-250), vosoritide and valoctocogene roxaparvovec and higher selling, general and administrative (SG&A) expense in support of the preparation for the commercial launch of Palynziq (formerly known as pegvaliase) and the continued commercial expansion of Brineura.

Non-GAAP Income for the second quarter of 2018 was $19.9 million, compared to Non-GAAP Income of $26.6 million in the second quarter of 2017. The decrease in Non-GAAP income in the second quarter of 2018 is primarily attributed to higher R&D and SG&A expenses, partially offset by increased gross profit from revenues.

As of June 30, 2018, BioMarin had cash, cash equivalents and investments totaling approximately $1.6 billion, as compared to $1.8 billion on December 31, 2017. Our 0.75% senior subordinated convertible notes due 2018 are scheduled to mature in October 2018. Holders have the right to convert their notes at maturity, and with respect to any such conversions we have elected to settle in cash up to the principal amount of the notes, shares of our common stock in respect of conversion value in excess thereof, and cash in lieu of any fractional shares.

Commenting on second quarter results, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, "In the quarter, BioMarin achieved numerous value-creating events on both the commercial and regulatory fronts. On May 24 we received standard FDA approval of Palynziq, an important new therapy that helps address a significant unmet need in adults with phenylketonuria (PKU) who have been unable to control their blood Phe levels with current treatment options. We are very happy with the pace of the initial commercial launch of Palynziq and look forward to providing an update on launch metrics in the third quarter of this year."

"In clinical development, we provided two years of clinical data with the 6e13 vg/kg dose of valoctocogene roxaparvovec gene therapy for severe Hemophilia A from the ongoing Phase 1/2 study in at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland. The updated data demonstrated the elimination of need for prophylaxis and no spontaneous bleeds in two years. In addition, we amended the protocol for the global GENEr8-1 (Phase 3) pivotal study to evaluate superiority compared to the current standard of care. The number of participants has been increased to 130 and we now anticipate completing enrollment during the first quarter of 2019."

Mr. Bienaimé continued, "With seven commercial products expected to generate approximately $1.5 billion in revenues this year, two potentially $1.0 billion plus late-stage clinical product opportunities, whose pivotal studies are expected to be fully enrolled later this year and in Q1 2019, I believe BioMarin's commercial prospects have never been better."

Updated August 2, 2018 Full-Year Financial Guidance ($ in millions, except %)

    Item          2018 Guidance                August 2, 2018
    ----          -------------                --------------


    Total
     Revenues                $1,470 to $1,530  Unchanged

    Kuvan Net
     Product
     Revenues                    $440 to $480  Unchanged

    Naglazyme Net
     Product
     Revenues                    $325 to $355  Unchanged

    Vimizim Net
     Product
     Revenues                    $460 to $500  Unchanged

    Brineura Net
     Product
     Revenues                      $35 to $55  Unchanged


    Cost of Sales
     (% of Total
     Revenues)                 20.0% to 21.0% Unchanged

    Research and
     Development
     Expense                     $645 to $685                 $680 to $710

    Selling,
     General and
     Admin.
     Expense                     $575 to $615  Unchanged


    GAAP Net Loss            $(115) to $(165)  Unchanged

    Non-GAAP
     Income *                    $100 to $140  Unchanged

    *All Financial Guidance items are
     calculated based on US GAAP with
     the exception of Non-GAAP Income.
     Refer to Non-GAAP Information
     beginning on page 9 of this press
     release for a complete discussion
     of the Company's Non-GAAP
     financial information and
     reconciliations to the comparable
     GAAP reported information.

Key Program Highlights

 

  • Palynziq for phenylketonuria: On May 24, 2018, the Company announced that it had received standard approval from the FDA for Palynziq, an injection to reduce blood Phe concentrations in adult patients with phenylketonuria, who have uncontrolled blood Phe concentrations greater than 600 micromoles/L on existing management. Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, is the first approved enzyme substitution therapy to target the underlying cause of PKU by helping the body to break down Phe. In the U.S., Palynziq is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palynziq REMS Program. Palynziq is BioMarin's second approved treatment for this important condition and its seventh commercialized product.

    In March 2018, the European Medicines Agency accepted BioMarin's submission of a Marketing Authorization Application for Palynziq.
     
  • Valoctocogene roxaparvovec gene therapy for hemophilia A:
    On May 22, the Company provided an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results were presented during an oral presentation at the WFH 2018 World Congress in Glasgow, Scotland by Dr. John Pasi, M.B., Ch.B., Ph.D., from Barts and The London School of Medicine and Dentistry and primary investigator for this Phase 1/2 study. The data presented at WFH is the most current data (April 16, 2018 cut off) and includes 104 weeks of data for the 6e13 vg/kg cohort and 52 weeks of data for the 4e13 vg/kg cohort.

    In the 6e13 vg/kg cohort, the data showed continued and substantial reductions in bleeding requiring Factor VIII infusions with a 97% reduction in mean Annualized Bleed Rate (ABR), with no spontaneous bleeds and elimination of all bleeds in target joints in the second year. 71% and 86% of participants had zero bleeds requiring Factor VIII infusions in years 1 and 2 respectively compared to 14%, who had zero bleeds requiring Factor VIII infusions for a year at baseline. There was a 96% reduction in mean FVIII usage through week 104. Mean Factor VIII activity levels from week 20 through 104 were consistently within the normal or near normal range and no participant was above the upper limit of normal at week 104, expressed as a percentage of normal factor activity in blood. At 104 weeks post-infusion, mean Factor VIII activity level of the 6e13 vg/kg cohort was within the normal range at 59%, and the median was near normal at 46%.

    Quality of life as measured by the six-domain Haemo-QoL-A instrument rapidly improved across all domains by up to 17.3 points in mean over baseline through the second year. This is well above the 5.2 point increase considered to be the minimal clinically important difference. The next data update on the Phase 1/2 study with the 6e13 vg/kg cohort is expected to be at the end of year three, in the May 2019 timeframe.

    The 4e13 vg/kg cohort also showed a substantial reduction in bleeding requiring Factor VIII infusions with a 92% reduction in ABR. 83% of participants had zero bleeds requiring Factor VIII infusions following treatment for a year compared to 17%, who had zero bleeds requiring Factor VIII infusions for a year at baseline. Mean Factor VIII usage decreased by 98%. Consistent with the reduction in ABR and FVIII usage, quality of life showed mean improvement by 3.8 to 6.3 points.

    The global Phase 3 program includes two studies with valoctocogene roxaparvovec, one with the 6e13 vg/kg dose (GENEr8-1) and one with the 4e13 vg/kg dose (GENEr8-2). Enrollment completion in the newly amended GENEr8-1 study is now expected in the first quarter of 2019. GENEr8-2, the ongoing Phase 3 study with the 4e13 vg/kg dose, remains unchanged with an N=40 and is expected to complete enrollment one to two quarters after GENEr8-1 in 2019.

    The Company updated the protocol for the GENEr8-1 study evaluating the 6e13 vg/kg dose and has powered the study to evaluate superiority to the current standard of care, Factor VIII prophylaxis. The study will now include 130 participants (an increase of 90 from the original 40).

    During the quarter, the Company began a Phase 1/2 study with the 6e13kg/vg dose of valoctocogene roxaparvovec in up to approximately 10 participants with pre-existing AAV5 antibodies. In addition to that study and the ongoing global Phase 3 studies, GENEr8-1 and GENEr8-2, BioMarin has two additional clinical studies underway in its comprehensive gene therapy program for the treatment of severe hemophilia A. One to study seroprevalence in people with severe hemophilia A and one non-interventional study to determine baseline characteristics in people with hemophilia A, are ongoing around the world. Also, participants in the Phase 1/2 dose escalation study updated in the quarter at WFH will continue to be monitored as part of the global program underway.
     
  • Vosoritide for achondroplasia: On May 11, 2018, the FDA held an advisory committee meeting to discuss drug development for the treatment of children with achondroplasia, the most common form of disproportionate short stature in humans. It was a joint meeting of the Pediatric Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee. The committees agreed that annualized growth velocity is the appropriate primary endpoint to use in clinical trials for the treatment of achondroplasia. The committees also expressed support for evaluating secondary endpoints in drug development for achondroplasia including, quality of life, and effects on sleep apnea, hearing loss, and ear infection.

    BioMarin's Phase 3 product candidate, vosoritide, an analog of C-type natriuretic peptide (CNP), is being studied in children with achondroplasia. Vosoritide has demonstrated sustained increase in average growth velocity over 30 months of treatment in 10 children, who completed 30 months of daily dosing at 15 µg/kg/day. Over this period of time, patients experienced a mean cumulative height increase of approximately 4 cm over what their baseline growth velocity would have predicted.

    The Company's multi-pronged program was developed to demonstrate the ability to improve clinical outcomes in children with achondroplasia. The program includes four distinct areas of focus to support global approval. Currently enrolling, the global Phase 3 study is a randomized, placebo-controlled study of vosoritide in approximately 110 children with achondroplasia ages 5-14 for 52 weeks. The study will be followed by a subsequent open-label extension. Children in this study will have completed a minimum six-month baseline study to determine their respective baseline growth velocity prior to entering the Phase 3 study. The baseline study is fully enrolled and the Company expects to complete enrollment of the Phase 3 study in September or October of this year. In addition, the Company expects to have over 5 years of clinical data from the long-term, open-label Phase 2 program to corroborate maintenance of effect.

    Given the importance of early intervention in this indication, on June 14, 2018, the Company began an infant/toddler study in 0 to 5 year-old children and dosed the first participant in the global Phase 2 study. Finally, the Company has undertaken a Natural History program to augment clinical understanding of outcomes of untreated patients for comparison to treated patients.

Other Ongoing Clinical Development Programs:

  • Tralesinidase alfa (formerly referred to as BMN 250) for MPS IIIB (Sanfilippo Syndrome, Type B): Earlier in the year, at the WORLDSymposium 2018, the Company updated preliminary results from the Phase 1/2 trial with tralesinidase alfa, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2) for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB). These data suggest that tralesinidase alfa, which is administered via intracerebroventricular (ICV) infusion, reaches the peripheral circulation and has activity in somatic organs. Development Quotient (DQ), a measure of cognitive function normalized to age, was also monitored. Preliminary data suggest stabilization of cognitive DQ at the high dose of tralesinidase alfa in some subjects. Patients with untreated Sanfilippo B syndrome usually show progressive decline in DQ.
     
  • BMN 290 for Friedreich's Ataxia: In late 2017, BioMarin announced that it had selected as its next clinical drug development candidate, BMN 290, a selective chromatin modulation therapy intended for treatment of Friedreich's ataxia. Friedreich's ataxia is a rare autosomal recessive disorder that results in disabling neurologic and cardiac progressive decline associated with a deficiency in frataxin. Prior to the lead compound being acquired by BioMarin from Repligen Corporation (Repligen), it demonstrated increases in frataxin in Friedreich's ataxia patients. In preclinical models conducted by BioMarin, BMN 290, a compound derived from the original Repligen compound, increases frataxin message expression in brain and cardiac tissues more than two-fold. Currently, there are no approved disease modifying therapies for Friedreich's ataxia. The Company expects to complete IND-enabling evaluations with a view to submitting an IND application for BMN 290 during the second half of 2018.
     
  • Gene therapy product candidate for phenylketonuria (PKU): In April 2018, the Company announced that it expects to submit an investigational new drug (IND) application for a gene therapy product for the treatment of PKU in 2019 (after BMN 290 for Friedreich's ataxia). PKU is an autosomal recessive disorder in which phenylalanine hydroxylase, the enzyme that metabolizes the amino acid phenylalanine (Phe), is deficient. PKU leads to high levels of neurotoxic phenylalanine, which affects neurocognitive development and function, if left untreated. In preclinical models, BioMarin's PKU gene therapy product candidate demonstrated sustained, normalized Phe levels in an ongoing study and out to 60 weeks at the last observation. The product candidate will be an AAV vector containing the DNA sequence that codes for the phenylalanine hydroxylase enzyme that is deficient in people with PKU.

BioMarin will host a conference call and webcast to discuss second quarter 2018 financial results today, Thursday, August 2, 2018 at 4:30 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.biomarin.com.

    U.S. /Canada Dial-in Number:
     866.502.9859                          Replay Dial-in Number: 855.859.2056
    ----------------------------           -----------------------------------

    International Dial-in Number:           Replay International Dial-in
     574.990.1362                           Number: 404.537.3406
    -----------------------------          -----------------------------

    Conference ID: 3364409                 Conference ID: 3364409
    ----------------------                 ----------------------

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of seven approved products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.

Forward-Looking Statements

This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the expectations of Total Revenues, Net Product Revenues and expenses for BioMarin's commercial products, GAAP Net Loss, Non-GAAP Income (Loss) and other specified income statement guidance; the financial performance of BioMarin as a whole; BioMarin's commercial prospects, including its expected $1.0 billion plus late-stage clinical product opportunities; the commercial launch of Palynziq; the timing of BioMarin's clinical studies and trials and announcements of data from those studies and trials, including BioMarin's Phase 3 program and Phase 1/2 study with valoctocogene roxaparvovec; the ongoing Phase 2 and Phase 3 studies of vosoritide and the Phase 1/2 study of tralesinidase alfa (formerly referred to as BMN 250); the continued clinical development and commercialization of BioMarin's commercial products and product candidates; including BioMarin's plans to file an IND for BMN 290 in the second half of 2018 and an IND for its new gene therapy candidate for the treatment of PKU in 2019; the possible approval and commercialization of BioMarin's product candidates. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's success in the commercialization of its commercial products; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, BioMarin's ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; actual sales of BioMarin's commercial products; the introduction of generic versions of BioMarin's commercial products, in particular generic versions of Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Brineura®, Firdapse®, Kuvan®, Naglazyme® and Vimizim® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. Palynziq™ is our trademark. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors:                   Media:

    Traci McCarty                Debra Charlesworth

    BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

    (415) 455-7558               (415) 455-7451

 

 

                                                                            BIOMARIN PHARMACEUTICAL INC.


                                                                       CONDENSED CONSOLIDATED BALANCE SHEETS

                                                                        June 30, 2018 and December 31, 2017

                                                         (In thousands of U.S. dollars, except share and per share amounts)


                                                                   June 30,                                                 December 31,
                                                                                                                                2017 (2)
                                                                     2018 (1)
                                                                      -------

                                   ASSETS                         (unaudited)

    Current assets:

    Cash and cash equivalents                                                                         $427,411                               $598,028

    Short-term investments                                                                             935,662                                797,940

    Accounts receivable, net                                                                           363,566                                261,365

    Inventory                                                                                          473,356                                475,775

    Other current assets                                                                                80,072                                 74,036
                                                                                                        ------                                 ------

    Total current assets                                                                             2,280,067                              2,207,144
                                                                                                     ---------                              ---------

    Noncurrent assets:

    Long-term investments                                                                              279,988                                385,785

    Property, plant and equipment, net                                                                 900,480                                896,700

    Intangible assets, net                                                                             502,295                                517,510

    Goodwill                                                                                           197,039                                197,039

    Deferred tax assets                                                                                425,380                                399,095

    Other assets                                                                                        39,430                                 29,852
                                                                                                        ------                                 ------

    Total assets                                                                                    $4,624,679                             $4,633,125
                                                                                                    ==========                             ==========

                    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities:

    Accounts payable and accrued liabilities                                                          $358,732                               $401,921

    Short-term convertible debt, net                                                                   369,752                                360,949

    Short-term contingent acquisition consideration                                                     76,466                                 53,648
                                                                                                        ------                                 ------

    Total current liabilities                                                                          804,950                                816,518

    Noncurrent liabilities:

    Long-term convertible debt, net                                                                    821,871                                813,521

    Long-term contingent acquisition consideration                                                      57,674                                135,318

    Other long-term liabilities                                                                         55,080                                 59,105
                                                                                                        ------                                 ------

    Total liabilities                                                                                1,739,575                              1,824,462
                                                                                                     ---------                              ---------

    Stockholders' equity:

    Common stock, $0.001 par value: 500,000,000 shares
     authorized;                                                                                           178                                    176
    177,508,163 and 175,843,749 shares issued and
     outstanding, respectively.

    Additional paid-in capital                                                                       4,577,300                              4,483,220

    Company common stock held by Nonqualified Deferred
     Compensation Plan                                                                                (13,390)                              (14,224)

    Accumulated other comprehensive loss                                                               (1,129)                              (22,961)

    Accumulated deficit                                                                            (1,677,855)                           (1,637,548)
                                                                                                    ----------                             ----------

    Total stockholders' equity                                                                       2,885,104                              2,808,663
                                                                                                     ---------                              ---------

    Total liabilities and stockholders' equity                                                      $4,624,679                             $4,633,125
                                                                                                    ==========                             ==========

    (1)              As of January 1, 2018, the
                     Company adopted the requirements
                     of Accounting Standards
                     Codification 606, Revenue from
                     Contracts with Customers (ASC
                     606), using the modified
                     retrospective method, and as a
                     result, there is a lack of
                     comparability of certain amounts
                     to the prior periods presented.


    (2)              December 31, 2017 balances were
                     derived from the audited
                     Consolidated Financial
                     Statements included in the
                     Company's Annual Report on Form
                     10-K for the year ended December
                     31, 2017, filed with the U.S.
                     Securities and Exchange
                     Commission on February 26, 2018.

 

 

 

                                                                                            BIOMARIN PHARMACEUTICAL INC.


                                                                                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                                                                  Three and Six Months Ended June 30, 2018 and 2017

                                                                              (In thousands of U.S. dollars, except per share amounts)

                                                                                                     (Unaudited)


                                                 Three Months Ended                          Six Months Ended

                                                      June 30,                                    June 30,
                                                      --------                                   --------

                                           2018 (1)                            2017                                             2018 (1)       2017
                                            -------                            ----                                              -------       ----

    REVENUES:

    Net product revenues                                             $367,786                                       $315,926                $736,885     $618,116

    Royalty and other revenues                                          5,059                                          1,522                   9,407        3,077
                                                                        -----                                          -----                   -----        -----

    Total revenues                                                    372,845                                        317,448                 746,292      621,193
                                                                      -------                                        -------                 -------      -------

    OPERATING EXPENSES:

    Cost of sales                                                      79,019                                         56,305                 161,352      106,311

    Research and development                                          175,582                                        143,039                 359,530      288,042

    Selling, general and administrative                               153,280                                        143,505                 291,616      263,524

    Intangible asset amortization and
     contingent consideration                                          10,227                                         13,411                  23,429       22,336

    Gain on sale of intangible assets                                (20,000)                                             -               (20,000)           -
                                                                      -------                                            ---                -------          ---

    Total operating expenses                                          398,108                                        356,260                 815,927      680,213
                                                                      -------                                        -------                 -------      -------

    LOSS FROM OPERATIONS                                             (25,263)                                      (38,812)               (69,635)    (59,020)


    Equity in the loss of BioMarin/Genzyme
     LLC                                                                (107)                                         (220)                   (39)       (743)

    Interest income                                                     5,569                                          2,983                  10,803        6,055

    Interest expense                                                 (12,225)                                      (10,040)               (23,787)    (20,159)

    Other income, net                                                   2,849                                            543                   2,677        4,015
                                                                        -----                                            ---                   -----        -----

    LOSS BEFORE INCOME TAXES                                         (29,177)                                      (45,546)               (79,981)    (69,852)

    Benefit from income taxes                                        (12,385)                                       (8,713)               (19,040)    (16,729)
                                                                      -------                                         ------                 -------      -------

    NET LOSS                                                        $(16,792)                                     $(36,833)              $(60,941)   $(53,123)
                                                                     ========                                       ========                ========     ========

    NET LOSS PER SHARE, BASIC AND DILUTED                             $(0.09)                                       $(0.21)                $(0.35)     $(0.31)
                                                                       ======                                         ======                  ======       ======

    Weighted average common shares
     outstanding, basic and dilutive                                  176,873                                        174,374                 176,405      173,547
                                                                      =======                                        =======                 =======      =======

    (1)              As of January 1, 2018, the
                     Company adopted the requirements
                     of ASC 606 using the modified
                     retrospective method, and as a
                     result, there is a lack of
                     comparability of certain amounts
                     to the prior periods presented.

Non-GAAP Information

The results presented in this press release for the three and six months ended June 30, 2018 and 2017 include both GAAP information and Non-GAAP information. As used in this release, Non-GAAP Income (Loss) is defined by the Company as GAAP Net Loss excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items, as detailed below when applicable. In addition, BioMarin includes in this press release the effects of these adjustments on certain components of GAAP Net Loss for each of the periods presented. In this regard, Non-GAAP Income (Loss) and its components, including Non-GAAP Cost of Sales, Non-GAAP Research and Development expenses, Non-GAAP Selling, General and Administrative expense, Non-GAAP Intangible Asset Amortization and Contingent Consideration, Non-GAAP Gain on the Sale of Intangible Asset and Non-GAAP Benefit From Income Taxes are statement of operations line items prepared on the same basis as, and therefore components of, the overall Non-GAAP measures.

BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non-GAAP Income (Loss) and its components are important internal measurements for BioMarin, the Company believes that providing this information in conjunction with BioMarin's GAAP information enhances investors' and analysts' ability to meaningfully compare the Company's results from period to period and to its forward looking guidance, and to identify operating trends in the Company's principal business. BioMarin also uses Non-GAAP Income (Loss) internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure.

Non-GAAP Income (Loss) and its components are not meant to be considered in isolation, as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP measures. Because of the non-standardized definitions, the Non-GAAP measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following table presents the reconciliation of GAAP Net Loss to Non-GAAP Income:

                                                       Reconciliation of GAAP Net Loss to Non-GAAP Income

                                                                 (In millions of U.S. dollars)

                                                                          (unaudited)


                                    Three Months Ended                            Six Months Ended                               Year Ending

                                         June 30,                                     June 30,                                December 31, 2018
                                       --------                                 --------

                                   2018                2017                                2018                          2017                          Guidance
                                   ----                ----                                ----                          ----                          --------


    GAAP Net Loss                         $(16.8)                         $(36.8)                                  $(60.9)                      $(53.1)                               $(115.0) - $(165.0)


      Interest expense, net                 6.7                              7.0                                      13.0                          14.1                      25.0 - 35.0

      Benefit from income taxes          (12.3)                           (8.7)                                   (19.0)                       (16.7)                    (40.0) - 0.0

      Depreciation expense                 13.5                             11.7                                      29.5                          23.7                      50.0 - 60.0

      Amortization expense                  7.5                              7.6                                      15.1                          15.1                                               30.0

      Stock-based compensation
       expense                             38.6                             40.0                                      75.2                          70.7                     150.0 - 170.0

      Contingent consideration
       expense                              2.7                              5.8                                       8.3                           7.2                      20.0 - 30.0

      Gain on sale of intangible
       assets                    (20.0)                               -                                   (20.0)                            -                   (20.0)
                                  -----                              ---                                    -----                           ---                    -----

    Non-GAAP Income                         $19.9                            $26.6                                     $41.2                         $61.0                                        $100 - $140
                                            =====                            =====                                     =====                         =====                                        ===========

The following reconciliation of the GAAP reported to the Non-GAAP information provides the details of the effects of the Non-GAAP adjustments on certain components of the Company's operating results for each of the periods presented.

                                                                                                                                    Reconciliation Of Certain GAAP Reported Information To Non-GAAP Information

                                                                                                                                                           (In millions of U.S. dollars)

                                                                                                                                                                    (Unaudited)


                                                                                                    Three Months Ended June 30.
                                                                                                    ---------------------------

                                                                                                        2018                                                                                       2017
                                                                                                        ----                                                                                       ----

                                                                                                      Adjustments                                                                                                                               Adjustments
                                                                                                      -----------                                                                                                                               -----------

                                      Interest,       Stock-Based             Interest,       Stock-Based
                                                                     Taxes,                                           Compensation,                                                                                Taxes,                   Compensation,
                                                                  Depreciation                                          Contingent                                                                              Depreciation                  Contingent
                                                                       and                                            Consideration                                                                                  and                    Consideration
                                                                  Amortization                                          and Other                                                                               Amortization                  and Other
                                    GAAP                                                                               Adjustments             Non-GAAP                               GAAP                                                   Adjustments            Non-GAAP

                                  Reported                                                                                                                                          Reported
                                  --------                                                                                                                                          --------


    Cost of sales                               $79.1                                       $                     -                                $(3.3)                                          $75.8                              $56.3                       $                 -         $(2.5)      $53.8

    Research and development                  175.6                                                         (7.9)                                (15.5)                                          152.2                              143.0                                     (6.2)         (14.6)      122.2

    Selling, general and
     administrative                           153.3                                                         (5.6)                                (19.8)                                          127.9                              143.5                                     (5.5)         (22.9)      115.1

    Intangible asset amortization
     and contingent consideration      10.2                                             (7.5)                                           (2.7)                                                -                                 13.4                          (7.6)                    (5.8)           -

    Gain on sale of intangible
     assets                          (20.0)                                                -                                            20.0                                                 -                                    -                             -                        -

    Interest expense, net             (6.7)                                              6.7                                                -                                                -                                (7.0)                           7.0                         -           -

    Benefit from income taxes        (12.3)                                             12.3                                                -                                                -                                (8.7)                           8.7                         -           -

    GAAP Net Loss/Non-GAAP Income            (16.8)                                                         15.4                                   21.3                                            19.9                             (36.8)                                     17.6            45.8        26.6



                                                                                                  Six Months Ended June 30,
                                                                                                  -------------------------

                                                                                                        2018                                                                                       2017
                                                                                                        ----                                                                                       ----

                                                                                                      Adjustments                                                                                                                               Adjustments
                                                                                                      -----------                                                                                                                               -----------

                                      Interest,       Stock-Based             Interest,       Stock-Based
                                                                     Taxes,                                           Compensation,                                                                                Taxes,                   Compensation,
                                                                  Depreciation                                          Contingent                                                                              Depreciation                  Contingent
                                                                       and                                            Consideration                                                                                  and                    Consideration
                                                                  Amortization                                          and Other                                                                               Amortization                  and Other
                                    GAAP                                                                               Adjustments             Non-GAAP                               GAAP                                                   Adjustments            Non-GAAP

                                  Reported                                                                                                                                          Reported
                                  --------                                                                                                                                          --------


    Cost of sales                              $161.4                                       $                     -                                $(6.4)                                         $155.0                             $106.3                       $                 -         $(4.8)     $101.5

    Research and development                  359.5                                                        (18.4)                                (28.8)                                          312.3                              288.0                                    (12.7)         (26.1)      249.2

    Selling, general and
     administrative                           291.6                                                        (11.1)                                (40.0)                                          240.5                              263.5                                    (11.0)         (39.8)      212.7

    Intangible asset amortization
     and contingent consideration      23.4                                            (15.1)                                           (8.3)                                                -                                 22.3                         (15.1)                    (7.2)           -

    Gain on sale of intangible
     assets                          (20.0)                                                -                                            20.0                                                 -                                    -                             -                        -           -

    Interest expense, net            (13.0)                                             13.0                                                -                                                -                               (14.1)                          14.1                         -           -

    Benefit from income taxes        (19.0)                                             19.0                                                -                                                -                               (16.7)                          16.7                         -           -

    GAAP Net Loss/Non-GAAP
     Income (Loss)                           (60.9)                                                         38.6                                   63.5                                            41.2                             (53.1)                                     36.2            77.9        61.0

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/biomarin-announces-second-quarter-2018-results-300690843.html

SOURCE BioMarin Pharmaceutical Inc.

Company Codes: NASDAQ-NMS:BMRN

Back to news